<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01442662</url>
  </required_header>
  <id_info>
    <org_study_id>SARCOME 11/1101</org_study_id>
    <secondary_id>2011-001308-36</secondary_id>
    <nct_id>NCT01442662</nct_id>
  </id_info>
  <brief_title>Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine</brief_title>
  <acronym>LMS03</acronym>
  <official_title>Phase II Multicenter Study to Determine the Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this research is to study the activity of pazopanib in second line after&#xD;
      anthracyclines in extra uterus and uterine LMS in association with gemcitabine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
      To determine the PFS using combination of gemcitabine and pazopanib in patients with&#xD;
      metastasis or relapse leiomyosarcoma (uterine or soft tissue)who have already received s&#xD;
      first line anthracycline based therapy.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      To determine the disease control rate To determine the response rate To determine toxicities&#xD;
      associated with combined gemcitabine and pazopanib To determine correlation between metabolic&#xD;
      response and PFS&#xD;
&#xD;
      Design:&#xD;
&#xD;
      All eligible patients entering the study will receive daily oral pazopanib at 800mg, supplied&#xD;
      as 200 mg aqueous film-coated tablets and 2 intravenous gemcitabine every three weeks (8&#xD;
      cycles max).&#xD;
&#xD;
      The treatment will continue until the development of unacceptable toxicity or evidence of&#xD;
      disease progression or until patient's / investigator's decision of withdrawal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2011</start_date>
  <completion_date type="Actual">May 28, 2019</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>9 months</time_frame>
    <description>To assess the 9-month Progression Free Survival in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas and treated with Gemcitabine and Pazopanib</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease control rate and overall response rate</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of the combination Gemcitabine-Pazopanib</measure>
    <time_frame>during the entire trial</time_frame>
    <description>The severity of the adverse events and toxicity will be graded according to the NCI CTC-AE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic response by using PET scan</measure>
    <time_frame>6 weeks</time_frame>
    <description>First PET scan at baseline and the second one at 6 weeks after the first administration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Leiomyosarcoma</condition>
  <arm_group>
    <arm_group_label>pazopanib, gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pazopanib + gemcitabine</intervention_name>
    <description>pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle</description>
    <arm_group_label>pazopanib, gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of metastatic or relapsed of uterine or soft tissue&#xD;
             leiomyosarcoma previously treated with one line of chemotherapy with at least an&#xD;
             anthracycline. Patients who have received adjuvant therapy less than one year before&#xD;
             relapse were considered to have received a first line therapy for metastatic disease)&#xD;
&#xD;
          -  Delay between the end of previous treatment (chemotherapy, hormonotherapy,&#xD;
             radiotherapy, immunotherapy, surgery or tumor embolisation) must be &gt; 4 weeks&#xD;
&#xD;
          -  At least one measurable lesion with RECIST criteria with progressive disease between&#xD;
             the last 6 weeks between inclusion. One target at least must be in a non irradiated&#xD;
             area&#xD;
&#xD;
          -  performance status ECOG ≤ 2&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Subjects must provide written informed consent prior to performance of study-specific&#xD;
             procedures, and must be willing to comply with treatment and follow up&#xD;
&#xD;
          -  Adequate hematologic function&#xD;
&#xD;
          -  Adequate coagulation function&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  Adequate liver function&#xD;
&#xD;
          -  Patients must be affiliated to a Social Health Insurance&#xD;
&#xD;
          -  Women of childbearing potential must be using a medically accepted method of&#xD;
             contraception and must have a negative serum pregnancy test within 14 days of&#xD;
             enrollment and/or urine pregnancy test 72 hours prior to the administration of the&#xD;
             first study treatment.&#xD;
&#xD;
          -  LVEF ≥ site limits&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Other uterine or soft tissue sarcomas&#xD;
&#xD;
          -  Symptomatic or known brain metastasis&#xD;
&#xD;
          -  Radiation therapy on the only evaluable lesion&#xD;
&#xD;
          -  Anti coagulant treatment&#xD;
&#xD;
          -  strong inhibitors or inducers of the isoenzyme CYP3A4 treatment&#xD;
&#xD;
          -  Known sero-positivity (HIV, HbC, HbS)or uncontrolled infection&#xD;
&#xD;
          -  other prior malignancy except basal cell skin cancer or carcinoma in situ of the&#xD;
             cervix&#xD;
&#xD;
          -  Clinically significant gastrointestinal abnormalities that may affect the absorption&#xD;
             of the IP&#xD;
&#xD;
          -  Corrected QT interval &gt; 480 msec&#xD;
&#xD;
          -  Other serious underlying pathology that would preclude study treatment&#xD;
&#xD;
          -  Calcium and magnesium levels inferior to standard levels (measured within 14 days&#xD;
             before the first pazopanib dose) and potassium levels inferior to standard levels&#xD;
             (measured within 72 hours before the first pazopanib dose)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Pautier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre G.F Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Val d'Aurelle Paul Lamarque</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest/Centre René Gauducheau</name>
      <address>
        <city>Nantes Saint Herblain</city>
        <zip>44806</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Hôpital Claudius Regaud</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Hopital René Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 10, 2011</study_first_submitted>
  <study_first_submitted_qc>September 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2011</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic or relapsed uterine or soft tissue leiomyosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>PD will not be shared at an individual level, they will be part of the study database including all enrolled patients</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

